Superior Planning, LLC’s Viking Therapeutics VKTX Stock Holding History

Superior Planning, LLC’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.54K	Buy	+78	New	+$2.7K	﹤0.01%	1478

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Superior Planning, LLC's VKTX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Viking Therapeutics (VKTX) in Q3 2026: 78 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #1478 among its holdings.

267 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

Superior Planning, LLC held 78 shares of Viking Therapeutics worth $2.54K as of Q3 2026.
Viking Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Viking Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1478 holding.
267 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.